Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?

Study Overview
=================
Brief Summary
-----------------
The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction in a large tertiary referral center. It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is superior to unfractionated heparin alone or bivalirudin alone. Additionally, after propensity matching this superiority remains.

Detailed Description
-----------------
This is a retrospective, observational, data analysis of approximately 800 patients who underwent primary Percutaneous Coronary Intervention at our institution since September 2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to Percutaneous Coronary Intervention will be excluded. This analysis is estimated to take 1-2 months.

Official Title
-----------------
Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?

Conditions
-----------------
ST-elevation Myocardial Infarction, Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Underwent Percutaneous Coronary Intervention at Washington Hospital Center since September 2000 Either received eptifibatide pre-or during PCI or have received no eptifibatide. Exclusion Criteria: Patients who received a thrombolytic prior to Percutaneous Coronary Intervention.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Eptifibatide Pre PCI<br>Receive eptifibatide pre PCI | |
| Eptifibatide during PCI<br>Receive eptifibatide during PCI | |
| No Eptifibatide<br>Receive no eptifibatide | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality and composite or Q-wave myocardial infarction | 6-month rates of all-cause mortality and the composite of all-cause mortality or Q-wave myocardial infarction. | Chart review 6 months after PCI | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TIMI major bleeding | Thrombolysis In Myocardial Infarction (TIMI) major bleeding during hospital stay. | During hospital stay; average stay is less than 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Major adverse microvascular integrity, all cause mortality, Q Wave MI